Ren F, Zhang L, Zhang X, Shi H, Wen T, Bai L, Zheng S, Chen Y, Chen D, Li L, Duan Z
Beijing Artificial Liver Treatment & Training Center, Beijing YouAn Hospital, Capital Medical University, Beijing, China.
Department of Infectious Diseases, The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, China.
Cell Death Dis. 2016 Mar 24;7(3):e2151. doi: 10.1038/cddis.2016.56.
Our previous studies have demonstrated that inhibition of glycogen synthase kinase 3β (GSK3β) activity protects mice from acute liver failure (ALF), whereas its protective and regulatory mechanism remains elusive. Autophagy is a recently recognized rudimentary cellular response to inflammation and injury. The aim of the present study was to test the hypothesis that inhibition of GSK3β mediates autophagy to inhibit liver inflammation and protect against ALF. In ALF mice model induced by D-galactosamine (D-GalN) and lipopolysaccharide (LPS), autophagy was repressed compared with normal control, and D-GalN/LPS can directly induce autophagic flux in the progression of ALF mice. Autophagy activation by rapamycin protected against liver injury and its inhibition by 3-methyladenine (3-MA) or autophagy gene 7 (Atg7) small interfering RNA (siRNA) exacerbated liver injury. The protective effect of GSK3β inhibition on ALF mice model depending on the induction of autophagy, because that inhibition of GSK3β promoted autophagy in vitro and in vivo, and inhibition of autophagy reversed liver protection and inflammation of GSK3β inhibition. Furthermore, inhibition of GSK3β increased the expression of peroxisome proliferator-activated receptor α (PPARα), and the downregulated PPARα by siRNA decreased autophagy induced by GSK3β inhibition. More importantly, the expressions of autophagy-related gene and PPARα are significantly downregulated and the activity of GSK3β is significantly upregulated in liver of ALF patients with hepatitis B virus. Thus, we have demonstrated the new pathological mechanism of ALF that the increased GSK3β activity suppresses autophagy to promote the occurrence and development of ALF by inhibiting PPARα pathway.
我们之前的研究表明,抑制糖原合酶激酶3β(GSK3β)的活性可保护小鼠免受急性肝衰竭(ALF)的影响,但其保护和调节机制仍不清楚。自噬是最近被认识到的对炎症和损伤的一种基本细胞反应。本研究的目的是验证以下假设:抑制GSK3β可介导自噬,从而抑制肝脏炎症并预防ALF。在由D-半乳糖胺(D-GalN)和脂多糖(LPS)诱导的ALF小鼠模型中,与正常对照相比,自噬受到抑制,并且D-GalN/LPS可在ALF小鼠病程中直接诱导自噬流。雷帕霉素激活自噬可保护肝脏免受损伤,而3-甲基腺嘌呤(3-MA)或自噬基因7(Atg7)小干扰RNA(siRNA)抑制自噬则会加重肝脏损伤。GSK3β抑制对ALF小鼠模型的保护作用取决于自噬的诱导,因为抑制GSK3β在体外和体内均可促进自噬,而抑制自噬则会逆转GSK3β抑制所带来的肝脏保护和炎症减轻作用。此外,抑制GSK3β可增加过氧化物酶体增殖物激活受体α(PPARα)的表达,而siRNA下调PPARα则会降低GSK3β抑制所诱导的自噬。更重要的是,在乙型肝炎病毒感染的ALF患者肝脏中,自噬相关基因和PPARα的表达显著下调,而GSK3β的活性显著上调。因此,我们已经证明了ALF的新病理机制,即GSK3β活性增加通过抑制PPARα途径抑制自噬,从而促进ALF的发生和发展。